AstraZeneca's Oncology and Rare Disease segments delivered 16% and 15% growth, powered by IMFINZI and ULTOMIRIS, respectively ...

AstraZeneca and Daiichi Sankyo received FDA approval for Enhertu in early-stage HER2-positive breast cancer in both ...

Both AstraZeneca and Roche lifted their respective full-year profit guidances in light of strong quarterly financials released Thursday morning. For AstraZeneca, total revenue increased 17% at ...

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Our strong growth momentum has continued into 2025 and we have now entered an unprecedented catalyst-rich period for our company. Already ...

Is AstraZeneca planning to peel off its China business? By CEO Pascal Soriot’s response to that question, it may only be a contingency plan. A Financial Times report last month suggested that ...